(redirected from escitalopram oxalate)
Also found in: Medical.


A drug of the SSRI class, C22H21FN2O, that is a stereoisomer of citalopram and is given in the form of its oxalate to treat depression and anxiety.

[es-, isomer pref. (pronunciation spelling of the first letter of S-stereoisomer, isomer with counterclockwise rotation, from Latin sinister, left-handed; see sinister) + citalopram.]


n escitalopram m
Mentioned in ?
References in periodicals archive ?
In Cece's case, escitalopram oxalate promotes weight gain, and if she is treated for diabetes with a sulfonylurea or thiazolidinedione, she will likely gain more weight.
Pharmaceutical company Teva Pharmaceutical Industries Ltd (Nasdaq:TEVA) reported on Wednesday the commercial launch of Escitalopram Oxalate Tablets in the US for the treatment of depression and generalised anxiety disorder.
The Food and Drug Administration has approved escitalopram oxalate for the treatment of generalized anxiety disorder.
Amneal Pharmaceuticals, LLC today announced the launch of Escitalopram Oxalate Oral Solution in 5 mg/5 mL strength, the first generic in liquid form on the market.
Persons Reporting Prescriptions for 10 Leading Psychiatric Drugs (a) Drug Name Mechanism Rank (Brand Name) of Action 1 Sertraline hydrochlolride SSRI (Zoloft) antidepressant 2 Citalopram hydrobromide SSRI (Celexa) antidepressant 3 Alprazolam (Xanax) Benzodiazepine 4 Zolpidem tartrate (Ambien) Hypnotic 5 Fluoxetine hydrochloride SSRI (Prozac) antidepressant 6 Trazodone hydrochloride SARI (Desyrel) antidepressant 7 Clonazepam (Klonopin) Benzodiazepine 8 Lorazepam (Ativan) Benzodiazepine 9 Escitalopram oxalate SSRI (Lexapro) antidepressant 10 Duloxetine hydrochloride SNRI (Cymbalta) antidepressant Reported Use, Prescriptions per Rank No.
68 Escitalopram Oxalate Accord 16729016901 5,293,433
In this study, patients who met DSM-IV([R]1) criteria for both insomnia and GAD were randomized to receive nightly LEXAPRO([R])brand escitalopram oxalate 10 mg, which is approved for the treatment of GAD, and either LUNESTA 3 mg (n=294) or placebo (n=301) for the first eight weeks, followed by a two-week period in which patients discontinued study drug but continued receiving escitalopram and placebo.